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Abstract 
BACKGROUND: Intrauterine Growth Restriction (IUGR) was defined as the growth of the fetus less than its 
normal potential growth due to genetic and environmental factors. One of the most widely believed causes of 
IUGR was impaired uteroplacental mechanism from mother to fetus. Furthermore, factor which was thought to 
affect placental growth was due to the influence of Brain-Derived Neurotrophic Factor (BDNF) and Matrix 
Metalloproteinase (MMP-9) which play an important role in angiogenesis. 
AIM: This study aims to determine differences in Brain-Derived Neurotrophic Factor (BDNF) and moderately 
mature Matrix Metalloproteinase (MMP-9) between normal birth weight and intrauterine growth restriction. 
MATERIAL AND METHODS: The study design was a cross-sectional study at four hospitals in Padang city from 
August 2017-January 2018. The sample of this study was umbilical cord blood of appropriate gestational age 
neonate with normal birth weight (31 neonates) and IUGR (31 neonates) by consecutive sampling, samples taken 
from mothers who meet inclusion criteria. BDNF and MMP-9 levels were analysed by ELISA. The differences 
between normal birth weight and IUGR test were followed by unpaired T-test. 
RESULTS: The results showed that BDNF levels in normal neonates was 1.58 ± 0.23 ng/ml and in IUGR 
neonates were 1.25 ± 0.35 ng/ml (p = 0.001). MMP-9 levels in normal neonates was 1.09 ± 0.20 ng/ml and in 
IUGR neonates were 1.25 ± 0.35 (p = 0.03). 
CONCLUSION: The conclusion of this study was BDNF of moderately mature neonates was significantly higher 
in normal birth weight compared to intrauterine growth restriction, and the moderately high MMP-9 neonates were 
significantly higher in intrauterine growth restriction compared with normal birth weight. 
 
 
 
 
 
 
Introduction 
 
IUGR is defined as fetal growth that is less 
than normal potential growth due to genetic and 
environmental factors. IUGR is included in the 
category of low birth weight babies (LBW) [1]. IUGR is 
assessed by looking at the baby's growth chart. IUGR 
was diagnosed when the baby was born with a low 
birth weight (below the 10th percentile) with clinical 
signs of malnutrition [2]. If intrauterine growth 
disorders occur early in the pregnancy, it will have an 
impact on the growth of the brain and skeletons which 
are disrupted by the result associated with poor nerve 
development [3]. 
IUGR affects around 24% of newborns where 
around 30 million babies worldwide suffer from IUGR 
each year. One third (75%) occurs in Asia; the rest 
occurs in Africa (20%) and Latin America (5%). 
Indonesia ranks fourth for IUGR cases from all 
countries in Asia after Sri Lanka, Cambodia and 
Vietnam [2]. The cause of IUGR tends to be due to a 
disruption of the uteroplacental mechanism from 
mother to fetus. The placenta is an organ that 
facilitates the exchange of gas and nutrients between 
mother and fetus. If there are abnormalities in the 
placenta, this exchange will be disrupted; the fetus will 
not get enough nutrients needed to grow which will 
eventually lead to IUGR [4]. 
One of the factors thought to influence the 
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process of placental growth is due to the influence of 
Brain-Derived Neurotrophic Factor (BDNF) and Matrix 
Metalloproteinase (MMP-9). In a study showed that 
there were differences in BDNF levels in the placenta 
in pregnant women with preeclampsia where a higher 
BDNF level was found in patients with normotensive 
[5]. in another study found that the absence of MMP-9 
in mice can cause severe abnormalities and lack of 
MMP-9 which causes disruption of trophoblast 
differentiation and the occurrence of defects in 
maternal blood vessels [6].  
BDNF is one of the proteins needed for the 
growth of neurons. During the development period, 
BDNF plays a role in nerve growth, differentiation, 
repair, and survival of nerve cells [7]. Also, BDNF also 
shows an important role during the implantation 
period, placental development and fetal growth 
development in mice [8]. BDNF is known to have an 
important role in regulating angiogenesis needed for 
placental development [9]. Because of this role, BDNF 
deficiency will disrupt placental growth which in turn 
will cause fetal growth disorders or intrauterine growth 
restriction (IUGR) [8]. 
There are several factors that affect BDNF 
levels, including age, sex, weight, iron deficiency 
anaemia and depression. BDNF is inversely 
proportional to age and weight. Getting older and 
getting heavier, the BDNF decreases. Research 
showed that respondents aged 20-33 years have 
BDNF higher than respondents aged > 34 years. 
Women also tend to have low BDNF compared to 
men. Depressed pregnant women also have low 
BDNF concentrations [10], [11]. The umbilical cord 
BDNF levels are also influenced by maternal ferritin, 
where levels tend to be lower in women with iron-
deficiency anaemia (< 12 ng/ml) than mothers with 
normal ferritin levels (≥ 12 ng/mL) [12]. 
Besides BDNF, another factor that affects 
placental growth is Matrix Metalloproteinase-9 (MMP-
9). MMP-9 is believed to facilitate trophoblast invasion 
with its role as the destroyer of the extracellular matrix 
in the process of placentation. MMP is known as a 
mediator in tissue remodelling and angiogenesis. If 
this process is interrupted, the trophoblast will not be 
embedded properly in the uterus. As a result, the 
distribution of nutrients to the fetus will also be 
disrupted which will eventually lead to IUGR. 
Based on the description above, the 
researcher wanted to conduct a study on the 
differences in Brain-Derived Neurotrophic Factor 
(BDNF) and the moderately mature Matrix 
Metalloproteinase (MMP-9) between normal birth 
weight and intrauterine growth restriction. This 
research is important to do with the hope that BDNF 
and MMP-9 placenta can be used as predictors to 
assess the occurrence of IUGR in pregnancy. The 
study was conducted in several hospitals in the city of 
Padang. 
 
Material and Methods 
 
This study was an observational study with 
cross-sectional [13]. This research was conducted 
from August 2017 to January 2018 at four hospitals in 
the city of Padang. Examination of BDNF and MMP-9 
levels was carried out at the Biomedical Laboratory, 
Andalas University, Padang. 
 
Population and Sample 
The population in this study was all month-old 
neonates who were admitted to several hospitals in 
Padang city at the time of the study. The inclusion 
criteria in this study were those who were willing to be 
the subjects of the study, the age of mothers 20-33 
years old, can remember HPHT or can show the 
results of TMG ultrasound examination 1, did not 
suffer from anemia (Hb11 gr/dl) and did not 
experience depression assessed from the 
questionnaire EPDS (Edinburgh Postnatal Depression 
Scale) (score > 13). Exclusion criteria are mothers 
with leukocytes > 13,000 mm
3
 and blood glucose 
when > 200 mg/dl.  
A total of 62 respondents as the study sample 
were taken using non-probability sampling methods 
by consecutive sampling. All subjects who came in 
sequence and fulfilled the inclusion criteria were 
included in the study until the required number of 
subjects was fulfilled [13]. 
Data normality test is done by using the 
Shapiro Wilk test. Data distribution is said to be 
normal if the significance value (sig) > 0.05). Data 
normality test was conducted to determine whether 
the data distribution of each variable. Data that is 
normally distributed is calculated on average and 
standard deviation. Bivariate analysis is used to 
determine the relationship between two variables. If it 
is normally distributed the unpaired t-test is used. 
 
How to take samples 
The method of sampling in this study is non-
probability sampling that is by card consecutive 
sampling. All subjects who arrived sequentially and 
fulfilled the inclusion criteria were included in the study 
until the number of subjects needed was met [13]. 
 
How to determine sample size 
Use the comparative numerical-numerical 
Lemeshow formula of two independent groups: 
Sample formula 
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n = Sample size, Zα = Error type 1 (α) of 5% = 
1.96, Zβ = Error type 2 (β) of 10% = 1.28, S = 
Combined standard deviation, (x1-x2) = the smallest 
difference clinically important (Determined by 
researchers). 
Because there are two variables examined by 
the researcher, then each sample size of the two 
variables will be searched for later compared to which 
sample size is greater. 
 
a. BDNF 
The standard deviation of the two groups is 
obtained based on the following calculations [14]: 
        
  
           
        
         
 
Sgab = Combined standard deviation 
S1 = Standard deviation of group 1 = 3.153 
n1 = Sample size of group 1 = 12 
S2 = Standard deviation of group 2 = 1.718 
n2 = Amount of sample group 2 = 34  
Based on the formula above, the combined 
deviation is obtained as follows: 
        
                            
        
 
Based on the formula above, the number of 
subjects is as follows: 
        
                    
     
 
 
          
 
b. MMP-9 
The standard deviation of the two groups is 
obtained based on the following calculations [15]: 
        
  
           
        
         
 
Sgab  = Combined standard deviation, S1 = 
Standard deviation of group 1 = 87.4, n1 = Sample 
size of group 1 = 24, S2 = Standard deviation of group 
2 = 53.37, n2  = Amount of sample group 2 = 38. 
Based on the formula above, the combined 
deviation is obtained as follows: 
        
                          
        
 
 
                       
Based on the formula above, the number of 
subjects is as follows: 
        
                 
     
 
 
      
Based on the calculation of the sample size of 
the two variables, the largest number of samples was 
taken, amounting to 28 people. To anticipate the 
subject who dropped out, the calculation was carried 
out as follows: 
  
 
   
 
  
  
     
 
  31,1 = 31, n = sample size = 28, f = 
estimated proportion of drop out = 10% = 0.1. 
After anticipating the drop-out subjects, the 
sample size was 32, so that the total sample taken 
was 62 people (31 enough months with IUGR and 31 
moderately-term neonates with normal birth weight). 
 
Taking Blood Serum 
Taking 3 ml umbilical cord blood sample using 
3 ml syringe conducted by officers and researchers. 
The blood taken is taken by the researcher into a 
centrifuge tube (vacutainer) without anticoagulation 
using the syringe handle which is allowed to bleed 
itself from the syringe tube. Blood in the vacutainer is 
placed on the tube rack to avoid shocks and remain in 
position. The blood is allowed to stand for 15-20 
minutes then centrifuged within 30 minutes at 3000 
rpm for 10 minutes. Blood that has been centrifuged 
and then taken by the serum using a micropipette is 
then inserted into the 1½ ml cup serum that has been 
coded according to the identity of the respondent. 
Blood samples that have hemolysis are removed. The 
sample serum is then put into the refrigerator at a 
temperature of 40-60°C (a maximum of 24 hours) and 
then sent to the Biomedical laboratory, Faculty of 
Medicine of the Andalas University using a cool box 
containing ice gel (which has been frozen for at least 
24 hours at -18°C) in time 4 hours. Deliveries will be 
made during laboratory working hours, namely at 
08.00-16.00 WIB. Then the serum is stored in the 
refrigerator -80°C until the examination is done. After 
all the serum is fulfilled, then BDNF levels are 
examined using the Human BDNF ELISA Kit and 
MMP-9 levels using the Human MMP-9 ELISA Kit at 
the Biomedical Laboratory of the Faculty of Medicine, 
Andalas University. 
 
Examination of BDNF Levels (Work 
protocol based on Human BDNF ELISA 
Kit) 
All reagents, samples and standards are 
prepared according to the instructions. All reagents 
and samples were left at room temperature 18-25°C 
before use. After that, 100 μL standard or sample is 
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added to each well then incubated for 2,5 hours at 
room temperature or overnight at 4°C. Then the 
prepared Streptavidin solution is then added to it for 
45 minutes at room temperature. After that 100 µL of 
TMB One-Step Substrate Reagent was added to each 
well then incubated for 30 minutes at room 
temperature. Finally added 50 µL Stop Solution at 
each well then read immediately with a wavelength of 
450 nm. Obtained the concentration value of the 
sample examined. 
 
Examination of MMP-9 Levels (Work 
protocol based on the Human MMP-9 
ELISA Kit) 
All reagents, samples and standards are 
prepared according to the instructions. All reagents 
and samples were left at room temperature 18-25°C 
before use. After that, 100 μL standard or sample is 
added to each well then incubated for 2.5 hours at 
room temperature or overnight at 4°C. Then the 
prepared Streptavidin solution is then added to it for 
45 minutes at room temperature. After that 100 µL of 
TMB One-Step Substrate Reagent was added to each 
well then incubated for 30 minutes at room 
temperature. Finally added 50 µL Stop Solution at 
each well then read immediately with a wavelength of 
450 nm. Obtained the concentration value of the 
sample examined.  
 
Data analysis 
The data normality test was carried out using 
the Kolmogorov Smirovov test (sample ≥ 50). Data 
distribution is said to be normal if the significance 
value (sig) > 0.05, and if sig < 0.05, the data is not 
normally distributed. Data normality test was 
conducted to determine whether the data distribution 
of each variable. Data that is normally distributed is 
calculated on average and standard deviation. Data is 
abnormally distributed, calculated median values and 
maximum minimums. Categorical data is calculated 
by frequency distribution.  
 
Research Ethics 
This research has received ethical 
considerations and approval from the Research Ethics 
Committee Team Faculty of Medicine of Andalas 
University with registration number 236/KEP/FK/2017.  
 
 
Results 
 
The normality test was carried out in groups 
using the Shapiro Wilk test. The test results in Table 1 
show that data are normally distributed (p > 0.05). 
Data with normal distribution will show the mean 
value. Then a comparative test of 2 unpaired groups 
was then carried out. 
Table 1: The characteristics of the research subject 
Characteristics Normal IUGR Ρ value 
Age of mother (year) 27 (2-33)
b
 28 (20-33)
b
 0.86 
IMT 22.61 ± 1.89
a
 22.05 ± 1.86
a
 0.25 
Hb level (g/dl) 11 (11-12.6)
 b
 11 (11-12.7)
 b
 0.98 
Level of GDS (g/dl) 93.52 ± 10.16
a
 94.65 ± 14.11
a
 0.72 
Leukocytes (/mm
3
) 9720.32 ± 1793.83
a
 10137.74 ± 19.09.06
 a
 0.38 
 
It can be seen that there is not one variable 
that has a significant difference in the two groups. 
This means that the characteristics of the two groups 
considered being homogeneous. 
 
Differences in BDNF Levels in Normal 
Babies and IUGR 
In the initial process of testing normal data 
distribution, the BDNF level shows normal data 
distribution which can be seen in Table 2. Therefore 
the data displayed is average. Table 2 shows that 
there are differences in BDNF levels between normal 
infants with IUGR. 
Table 2: BDNF levels for each group of research subjects 
 
N 
BDNF Levels (ng/mL) 
Ρ value 
Mean SD 
Normal  31 1.58 0.23 
0.001* 
IUGR  31 1.25 0.35 
* p < 0.05. Independent t-test. 
 
Differences in MMP-9 Levels in Normal 
Babies and IUGR 
In the initial process of testing the distribution 
of normal data, MMP-9 levels show normal data 
distribution which can be seen in Table 3. Therefore 
the data displayed is in the form of a mean.  
Table 3: MMP-9 levels for each group of research subjects 
 N MMP-9 Levels (ng/mL) Ρ value 
Mean SD 
Normal 31 1.09 0.20 0.03* 
IUGR 31 1.25 0.35 
* p < 0.05. Independent t-test. 
 
Table 3 above shows that there are 
differences in MMP-9 levels between normal infants 
with IUGR. 
 
 
Discussion 
 
Differences in BDNF Levels in Normal 
Babies and IUGR 
There were significant differences between 
the median BDNF levels in normal infants, which were 
1.58 ± 0.23 ng/ml and BDNF levels in IUGR infants 
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were 1.25 ± 0.35 ng/ml which can be seen in Table 2. 
Previous studies have shown that a decrease 
in serum BDNF at the end of pregnancy is associated 
with a risk of low birth weight [16]. Also, other studies 
have also found the role of BDNF in energy 
angiogenesis and homeostasis in the uteroplacental 
system which allows in influencing the aetiology 
associated with impaired placental growth and the 
fetus including one of them IUGR [8]. 
One of the most studied neurotrophin 
members is BDNF. Several studies have highlighted 
the critical role of neurotrophin in particular NGF and 
BDNF during pregnancy [14]. BDNF has been 
reported to have a role in embryo implantation, 
placental development, fetal growth from mid-
gestational to advanced gestation by increasing 
trophoblast cell growth and survival in mice 
suggesting a possible role in the development of 
fetoplacental units [17]. 
In the study stated that one of the forms of 
neurotrophin is BDNF, a molecule that regulates 
placental and brain development. Placental 
development is very important during pregnancy 
because it forms the interface between the maternal-
fetal circulation and is essential for fetal nutrition and 
oxygenation. Also, BDNF also tends to influence the 
birth and development of neurons through two 
mechanisms, namely angiogenesis and cell growth, 
defence and maturation [18]. 
However, in other studies, there were no 
significant differences in BNDF levels when observed 
between term infants with IUGR and term infants with 
normal birth weight (AGA/Age of Proper Pregnancy) 
measured from the mother, fetus, and neonatal side. 
This result may be due to differences in the 
characteristics of the sample under study where more 
criteria are used in determining the sample to be 
taken. These criteria include the presence or absence 
of polyhydramnios, congenital infections, and 
chromosome assessment for mothers over 35 years 
to assess the risk of fetal anomalies. Also, the 
assessment of smoking behaviour and drinking habits 
is also assessed. This study also included mothers 
with severe anaemia and diabetes while both were 
exclusion criteria in this study [19]. 
 
Differences in MMP-9 Levels between 
Normal Babies and IUGR 
There is a difference between MMP-9 levels 
in normal infants which is 1.09 ± 0.20 ng/ml and the 
mean MMP-9 level in IUGR infants is 1.25 ± 0.35 
ng/ml which can be seen in Table 3. 
In line with the research conducted who found 
that placentas from pregnancies with IUGR showed a 
decrease in the release of MMP-2, MMP-9 and TIMP-
1 compared to normal pregnancies [20]. Other studies 
also found that a decrease in MMP-9 levels affected 
the pathological processes underlying the occurrence 
of preeclampsia and IUGR in both preeclampsias and 
normal pregnancies with IUGR [21]. Different results 
were found in other studies that MMP-9 levels had no 
significant relationship with gestational age and infant 
birth weight. These different results may be due to 
using premature infants as respondents while this 
study assessed fairly month’s infants [22]. 
Matrix metalloproteinases (MMPs) are 
members of the protease family that can degrade 
extracellular matrix (ECM) and connective tissue 
proteins [23]. MPMP-9 is expressed by the uterus and 
plays a role in remodelling uterine tissue in the estrus 
cycle, menstrual cycle and pregnancy in both animals 
and humans. MMP-9 has also been found to increase 
in the myometrium and aorta of pregnant mice which 
shows its role in the uterus and vascular remodelling 
MMP-9 also plays a role in angiogenesis by allowing 
endothelial cells to escape and move into new tissues 
and also by releasing proangiogenic factor matrix [24]. 
MMPs are families of zinc-dependent 
endopeptidases that divide the ECM component and 
are involved in embryo implantation, placental 
development and also in the process of labour. 
Research shows that the development of the 
maternal-fetal circulation and the success of 
pregnancy in humans require the invasion of 
trophoblast cells into the endometrial stroma and the 
lining in all three myometria. This invasion ability is 
mediated by MMPs where the most important role is 
held by MMP-9 [5].  
Deficiency of MMP-9 can disrupt trophoblast 
invasion and will lead to abnormal and superficially 
implanted placenta as in preeclampsia. Low MMP-9 
levels are found in patients with preeclampsia and 
cases of IUGR [5]. Experiments in pregnant rats 
proved that placentas that did not have MMP-9 
showed smaller implantation spaces and embryos 
with a significantly reduced body weight that matched 
the characteristics of IUGR [6]. 
In this study only assessing IUGR, not 
classifying whether symmetrical or asymmetrical. This 
research can use to determine the aetiology and 
pathophysiology of IUGR by looking at BDNF and 
MMP-9 levels and as a preventive measure in 
preventing the occurrence of IUGR in pregnant 
women by avoiding the risk factors for low BDNF 
levels, namely age (< 20 or > 33 years), iron 
deficiency anemia (Hb < 11gr /dl), and avoiding 
depression as assessed from the EPDS questionnaire 
(Edinburgh postnatal depression scale) (score < 13). 
In a cross-sectional study, IUGR can be diagnosed if 
the neonatal body weight is below the 10th percentile 
based on the Lubchenco growth curve. Pretty month 
neonates who were born at 37 to 42 weeks' gestation 
were weighed within < 24 hours. 
In conclusion, BDNF of moderately mature 
neonates was significantly higher in normal birth 
weight compared to intrauterine growth restriction and 
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the moderately high MMP-9 neonates were 
significantly higher in intrauterine growth restriction 
compared with normal birth weight. 
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